A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are δ/μ opioid receptor agonists and neurokinin 1 receptor antagonists

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1369-1376

  Yamamoto, Takashi ^a   Nair, Padma ^a   Vagner, Josef ^a   Largent Milnes, Tally ^b   Davis, Peg ^b   Ma, Shou Wu ^b   Navratilova, Edita ^b   Moye, Sharif ^b   Tumati, Suneeta ^b   Lai, Josephine ^b   Yamamura, Henry I ^b   Vanderah, Todd W ^b   Porreca, Frank ^b   Hruby, Victor J ^a  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL AMIDE DERIVATIVE; BIPHALIN; CARBOXYL GROUP; DELTA OPIATE RECEPTOR AGONIST; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NEUROKININ 1 RECEPTOR ANTAGONIST; PEPTIDE; PEPTIDE DERIVATIVE; SUBSTANCE P; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DRUG SYNTHESIS; GENE ACTIVATION; GUINEA PIG; ILEUM; MOUSE; NONHUMAN; PROTEIN INTERACTION; SOLID; STRUCTURE ACTIVITY RELATION; VAS DEFERENS;

ANIMALS; CELL LINE; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; CRICETINAE; CRICETULUS; ELECTRIC STIMULATION; GUINEA PIGS; HUMANS; ILEUM; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RECEPTORS, NEUROKININ-1; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 41649107460     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070332f     Document Type: Article

References (49)

1. Yaksh, T. L. Spinal opiate analgesia: characteristics and principles of action. Pain 1981, 11, 293-346.
2. Ossipov, M. H.; Lai, J.; King, T.; Vanderah, T. W.; Porreca, F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 2005, 80, 319-324.
3. Kalso, E. Improving opioid effectiveness: from ideas to evidence. Eur. J. Pain 2005, 9, 131-135.
4. Datar, P.; Srivastava, S.; Coutinho, E.; Govil, G. Substance P: structure, function, and therapeutics. Curr. Top Med. Chem. 2004, 4, 75-103.
5. King, T.; Ossipov, M. H.; Vanderah, T. W.; Porreca, F.; Lai, J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005, 14, 194-205.
6. King, T.; Gardell, L. R.; Wang, R.; Vardanyan, A.; Ossipov, M. H.; Malan, T. P., Jr.; Vanderah, T. W.; Hunt, S. P.; Hruby, V. J.; Lai, J.; Porreca, F. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005, 116 (3), 276-288.
7. King, T.; Ossipov, M. H.; Vanderah, T. W.; Porreca, F.; Lai, J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance. Neurosignals 2005, 14 (4), 194-205.
8. Ma, W.; Zheng, W. H.; Kar, S; Quirion, R. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience 2000, 99 (3), 529-539.
9. Powell, K. J.; Quirion, R.; Jhamandas, K. Inhibition of neurokinin-1 - substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur. J. Neurosci. 2003, 18 (6), 1572-1583.
10. Misterek, K.; Maszczynska, I.; Dorociak, A.; Gumulka, S. W.; Carr, D. B.; Szyfelbein, S. K.; Lipkowski, A. W. Spinal co-administration of peptide substance P antagonist increases antinociceptive effect of the opioid peptide biphalin. Life Sci. 1994, 54 (14), 939-944.
11. Gu, G.; Kondo, I.; Hua, X. Y.; Yaksh, T. L. Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence. J. Pharmacol. Exp. Ther. 2005, 3/4 (3), 1362-1369.
12. Hökfelt, T.; Kellerth, J.; Nilsson, G.; Pernow, B. Substance P: localization in the central nervous system and in some primary sensory neurons. Science, 1975, 190, 889-890.
13. Marchand, J. E.; Kream, R. M. The glycine-extended SP precursor, SP-G, is normally expressed in SP-containing neurons, in Substance P and Related Peptides: Cellular and Molecular Physiology. Leeman S. E., Krause J. E., Lembeck, F. eds.; New York Academy of Sciences: New York, 1990.
14. Aicher, S. A.; Sharma, S.; Cheng, P. Y.; Chen, L. Y. L.; Pickel, V. M. Dual Ultrastructural Localization of μ-Opiate Receptors and Substance P in the Dorsal Horn. Synapse 2000, 36, 12-20.
15. Yamamoto, T.; Nair, P.; Davis, P.; Ma, S. W.; Navratilova, E.; Moye, M.; Tumati, S.; Vanderah, T. W.; Lai, J.; Porreca, F.; Yamamura, H. I.; Hruby, V. J. Design, Synthesis and Biological Evaluation of Novel Bifunctional C-terminal Modified Peptides for δ/μ Opioid Receptor Agonists and Neurokinin-1 Receptor Antagonists. J. Med. Chem. 2007, 50 (12), 2779-2786.
16. Yamamoto, T.; Nair, P.; Davis, P.; Ma, S. W.; Moye, S.; Largent, T.; Vanderah, T. W.; Lai, J.; Porreca, F.; Yamamura, H. I.; Hruby, V. J. Design, Structure-Activity Relationships and Biological Evaluation of Novel Bifunctional C-terminal Modified Peptides for δ/μ Opioid Receptor Agonists and Neurokinin-1 Receptor Antagonists. 232nd ACS National Meeting, San Francisco, CA, United States, Sep. 10-14, 2006; p MEDI-7. The in vivo result presented at the conference is also available in the Supporting Information.
17. Foran, S. E.; Carr, D. B.; Lipkowski, A. W.; Maszczynska, I.; Marchand, J. E.; Misicka, A.; Beinborn, M.; Kopin, A. S.; Kream, R. M. Inhibition of morphine tolerance development by a substance P-opioid peptide chimera. J. Pharmacol. Exp. Ther. 2000, 295 (3), 1142-1148.
18. Bonney, I. M.; Foran, S. E.; Marchand, J. E.; Lipkowski, A. W.; Carr, D. B. Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties. Eur. J. Pharmacol. 2004, 488 (1-3), 91-99.
19. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48 (21), 6523-6543.
20. Lee, Y. S.; Agnes, R. S.; Badghisi, H.; Davis, P.; Ma, S. W.; Lai, J.; Porreca, F.; Hruby, V. J. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J. Med. Chem. 2006, 49 (5), 1773-1780.
21. Agnes, R. S.; Lee, Y. S.; Davis, P.; Ma, S. W.; Badghisi, H.; Porreca, F.; Lai, J.; Hruby, V. J. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J. Med. Chem. 2006, 49 (10), 2868-2875.
22. Hruby, V. J.; Agnes, R. S.; Davis, P.; Ma, S. W.; Lee, Y. S.; Vanderah, T.W.; Lai, J.; Porreca, F. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci. 2003, 73 (6), 699-704.
23. Horan, P. J.; Mattia, A.; Bilsky, E. J.; Weber, S.; Davis, T. P.; Yamamura, H. J.; Malatynska, E.; Appleyard, S. M.; Slaninova, J.; Misicka, A.; Lipowski, A. W.; Hruby, V. J.; Porreca, F. Antinociceptive Profile of Biphalin, a Dimeric Enkephalin Analog. J. Pharmacol. Exp. Ther. 1993, 265, 1446-1454.
24. Gentilucci, L. New Torends in the Development of Opioid Peptide Analogues as Advanced Remedies for pain Relief. Curr. Top. Med. Chem. 2004, 4, 19-38.
25. 2 deduced from two-dimensional 1H-NMR and conformational energy calculations is related to its affinity for NK1-receptor. J. Pept. Sci 2001, 7 (6), 323-330.
26. 2 as NK1/NK2 ligands. Lett. Pep. Sci. 1999, 6, 255-262.
27. Macleod, A. M.; Merchant, K. J.; Cascieri, M. A.; Sadowski, S.; Ber, E.; Swain, C. J.; Baker, R. N-Acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists. J. Med. Chem. 1993, 14, 2044-2045.
28. Lewis, R. T.; Macleod, A. M.; Merchant, K. J.; Kelleher, F.; Sanderson, I.; Herbert, R. H.; Cascieri, M. A.; Sadowski, S.; Ball, R. G.; Hoogsteen, K. Tryptophan-derived NK1 antagonists: conformationally constrained heterocyclic bioisosteres of the ester linkage. J. Med. Chem. 1995, 38, 923-933.
29. Sasubilli, R.; Gutheil, W. General Inverse Solid Phase Synthesis Method for C-Terminally Modified Peptide Mimetics. J. Comb. Chem. 2004, 6, 911-915.
30. Aisina, J.; Albercio, F. Solid-phase synthesis of C-terminal modified peptides. Biopolymres 2003, 71, 454-477.
31. Chan, W. C.; White, P. D. Fmoc Solid Phase Peptide Synthesis A Practical Approach; Oxford University Press: New York, 2000.
32. Egleton, R. D.; Mitchell, S. A.; Huber, J. D.; Janders, J.; Stropova, D.; Polt, R.; Yamamura, H. I.; Hruby, V. J.; Davis, T. P. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res. 2000, 881, 37-46.
33. Saria, A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. 1999, 375 (1-3), 5160. and references therein.
34. Tooneya, P. A.; Andersona, W. B.; Lynch-Frameb, A.; Chahla, L. A. The effects of haloperidol treatment on the distribution of NK1 receptor immunoreactive neurons in guinea-pig brain. Neurosci. Lett. 2005, 383 (1-2), 155-159.
35. Field, M. J.; McCleary, S.; Boden, P.; Suman-Chauhan, N.; Hughes, J.; Singh, L. Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat. J. Pharmacol. Exp. Ther. 1998, 285 (3), 1226-1232.
36. Barr, A. J.; Watson, S. P. Non-peptide antagonists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors. Br. J. Pharmacol. 1993, 108 (1), 223-227.
37. Cascieri, M. A.; Macleod, A. M.; Underwood, D.; Shiao, L. L.; Ber, E.; Sadowski, S.; Yu, H.; Merchant, K. J.; Swain, C. J.; Strader, C. D.; Fong, T. M. Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J. Biol. Chem. 1994, 269 (9), 6587-6591.
38. Braunschweiler, L.; Ernst, R. R. Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy. J. Magn. Reson. 1983, 53, 521-528.
39. Davis, D. G.; Bax, A. Assignment of complex 1H-NMR spectra via two-dimensional homonuclear Hartmann-Hahn spectroscopy. J. Am. Chem. Soc. 1985, 107, 2820-2821.
40. Subramanian, S.; Bax, A. Generation of pure phase NMR subspectra for measurement of homonuclear coupling constants. J. Magn. Reson. 1987, 71, 325-330.
41. Ranee, M. Improved techniques for homonuclear rotating-frame and isotropic mixing experiments. J. Magn. Reson. 1987, 74, 557-564.
42. Bax, A.; Davis, D. G. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 1985, 65, 355-360.
43. Marion, D.; Wüthrich, K. Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun. 1983, 113, 967-974.
44. Braunschweiler, L.; Ernst, R. R. Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy. J. Magn. Reson. 1983, 53, 521-528.
45. Boyd, N. D.; Kage, R.; Dumas, J. J.; Krause, J. E.; Leeman, S. E. The peptide binding site of the substance P (NK-1) receptor localized by a photoreactive analogue of substance P: presence of a disulfide bond. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 433-437.
46. 35S]thio)triphosphate binding. Mol. Pharmacol. 1993, 44 (1), 115-123.
47. Porreca, F.; Burks, T. F. Affinity of normorphine for its pharmacologic receptor in the naive and morphine-tolerant guinea-pig isolated ileum. J. Pharmacol. Exp. Ther 1983, 225 (3), 688-693.
48. Porreca, F.; LoPresti, D.; Ward, S. J. Opioid agonist affinity in the guinea-pig ileum and mouse vas deferens. Eur. J. Pharmacol. 1990, 179 (1-2), 129-139.
49. Lipkowski, A. W.; Misicka, A.; Davis, P.; Stropova, D.; Janders, J.; Lachwa, M.; Porreca, F.; Yamamura, H. I.; Hruby, V. J. Biological activity of fragments and analogues of the potent dimeric opioid peptide, biphalin. Bioorg. Med. Chem. Lett. 1999, 9 (18), 2763-2766.